Barclays
ORIC icon

Barclays’s Oric Pharmaceuticals ORIC Stock Holding History

Barclays’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
19,807
+7,378
+59% +$66.9K ﹤0.01% 3648
2026
Q1 		$157K Sell
12,429
-706,106
-98% -$8.02M ﹤0.01% 3828
2025
Q4 		$5.88M Buy
718,535
+534,444
+290% +$6.15M ﹤0.01% 2092
2025
Q3 		$2.21M Buy
184,091
+41,410
+29% +$436K ﹤0.01% 2816
2025
Q2 		$1.45M Buy
142,681
+40,891
+40% +$275K ﹤0.01% 3090
2025
Q1 		$568K Sell
101,790
-12,902
-11% -$113K ﹤0.01% 3447
2024
Q4 		$926K Buy
114,692
+7,431
+7% +$68.2K ﹤0.01% 3424
2024
Q3 		$1.1M Buy
107,261
+56,474
+111% +$558K ﹤0.01% 3297
2024
Q2 		$359K Buy
50,787
+17,633
+53% +$158K ﹤0.01% 3241
2024
Q1 		$456K Sell
33,154
-21,045
-39% -$250K ﹤0.01% 3650
2023
Q4 		$499K Buy
54,199
+46,484
+603% +$336K ﹤0.01% 3875
2023
Q3 		$46.7K Sell
7,715
-57
-0.7% -$467 ﹤0.01% 3901
2023
Q2 		$60.3K Buy
+7,772
New +$44.1K ﹤0.01% 3756
2022
Q2 		– Sell
-5,252
Closed -$29K – 5195
2022
Q1 		$29K Buy
+5,252
New +$47.3K ﹤0.01% 4313

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's ORIC Position: Q2 2026 in Review

Barclays increased its Oric Pharmaceuticals (ORIC) stake by 59% in Q2 2026, buying an estimated $66.9K and bringing the position to 19,807 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

Barclays first reported a position in ORIC in Q1 2022 and has held it in 14 quarters since. The position peaked at $5.88M in Q4 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Barclays held 19,807 shares of Oric Pharmaceuticals worth $215K as of Q2 2026.
  • Barclays bought 7,378 Oric Pharmaceuticals shares in Q2 2026, an estimated $66.9K.
  • Oric Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3648 holding.
  • Barclays first reported a position in Oric Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Barclays's Oric Pharmaceuticals position peaked at $5.88M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.